Click here to read the full article.
The U.S. Centers for Disease Control and Prevention (CDC) recently released new data suggesting that cases of post-COVID-19 vaccine-linked heart inflammation among young males have risen.
Recent figures published in the CDC’s Vaccine Safety Datalink surveillance system show that within a week of getting the two-dose Pfizer-BioNTech vaccine, there were 14 confirmed cases of myocarditis or pericarditis among 102,091 males between the ages of 16 and 17. And of the 206,000 12- to 15-year-old males who got the same two-dose vaccine series, 31 cases were confirmed in a week, according to the data (pdf).
In August 2021, the CDC reported 42.6 myocarditis and pericarditis cases per million and 71.5 per million for 12- to 15-year-old males and 16- to 17-year-old males, respectively. That breaks down to about one in 23,500 for the younger group and around one in 14,000 for the older group.
But with last week’s report, the CDC said that the incident rate for the 12- to 15-year-old group is 150.5 per million—or about 1 in 6,600—and 137.1 per million for the 16- to 17-year-old group—or about 1 in 7,262.
Following the first booster dose, CDC figures show that it jumps to 188 per million among the 16- to 17-year-old group. But for the 12- to 15-year-old males, 61.3 per million developed heart inflammation after the booster dose, according to the figures.
The CDC’s report, issued by CDC researcher Tom Shimabukuro, was published on Sept. 1.
In its report, the CDC noted that “myocarditis is a rare event following mRNA COVID-19 booster vaccination” and that it has “verified 131 myocarditis case reports to VAERS in people ages [5 years and older] after 123,362,627 million mRNA COVID-19 booster vaccinations.”
In analyses of the data, “myocarditis [and] pericarditis incidence following first booster dose and dose 2 of the primary series are similar, though case counts are small and confidence intervals around point estimates are wide,” said the CDC.
The Vaccine Safety Datalink is described by the agency as “a collaborative project between CDC’s Immunization Safety Office and nine health care organizations” and is designed to “monitor [the] safety of vaccines and conduct studies about rare and serious adverse events following immunization.”
In May, the CDC said reports of heart inflammation linked to the Pfizer vaccine were much lower in 5- to 11-year-old boys than in adolescents and young males. At the time, the CDC stated the rate of reports for myocarditis in the vaccine reporting system in 5- to 11-year-old boys after the second dose of the vaccine was 2.7 cases per million.
A study that was led by Dr. Tracy Hoeg, with the Florida Department of Health, and released in mid-2021 showed similar figures.
Hoeg and others uploaded a preprint study showing a rate of 94 instances of myocarditis per million in 16- to 17-year-old males—or 1 in 10,6000—and 162 per one million in 12- to 15-year-old males—or 1 in 6,200—she wrote on Sept. 1.
The CDC “is now finally catching up & reporting similar,” Hoeg wrote on Twitter, noting their study was released more than a year ago.
“If we hadn’t been villified as ‘anti-vaxxers’ spreading ‘mis’ & ‘disinformation,’ how would the conversation around minimizing the chance of this adverse event have changed & how many cases of myo/pericarditis in young males would have been prevented over the last year?” she asked.
Hoeg also questioned recent statements made by CDC officials in recommending boosters to anyone aged 12 and older.
“Now today the CDC is recommending with no human data on benefits or risks that *everyone* 12 and up get a bivalent booster. ‘There is no bad time to get your COVID-19 booster.’ Really?” she asked. “Why are nuance & individualized recs so difficult for @CDCgov?”
The Epoch Times has contacted CDC for comment.
Continue reading here.
Scroll down for comments and share your thoughts!